Emma Guttman-Yassky, MD, PhD, discusses REZOLVE-AD biomarker data showing early Treg and inflammatory changes with rezpegaldesleukin from EADV 2026.
Emma Guttman-Yassky, MD
Advertisement
Waldman Professor of Dermatology and Immunology, health system chair of the Kimberly and Eric J. Waldman Department of Dermatology, and director of the Laboratory for Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sina
Articles by Emma Guttman-Yassky, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss
2
Experts Discuss PAH Treatment Selection and Access
3
ABCs in Dermatology: Topical PDE4 Inhibition in Atopic Dermatitis
4
CONCORD Trial Results in CKD Depression, With Susan Hedayati, MD, MHSc
5